Compare Amgen, Inc. (AMGN) vs Alibaba Group (BABA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Alibaba Group — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Alibaba Group trades at $112.85 (market cap $269.48B). The key difference: Alibaba Group is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | BABA | |
|---|---|---|
Market Cap | $196.12B | $269.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $189.34 |
52-Week Low | $271.18 | $94.83 |
Enterprise Value | $241.41B | $264.31B |
Dividend Yield | 2.77% | 0.93% |
Volume | — | 18,069,938 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Alibaba (BABA) trades at $112.33, up 1.07% today, with a bullish technical signal and strong analyst consensus. Recent earnings misses contrast with improving fundamentals, including a 13.05% net margin and $130.11B net income for 2025. The stock faces headwinds from securities investigations but benefits from AI momentum and narrowing losses in quick commerce.
Outlook remains positive with an 86% buy rating and $195 consensus target, though risks include regulatory scrutiny and earnings volatility. Upside potential hinges on execution in cloud and e-commerce, while legal overhangs and macroeconomic pressures pose near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →
